Borrowing a chapter from venture capitalists, the U.S.’ Biomedical Advanced Research and Development Authority (BARDA) is partnering with the nonprofit Global Health Investment Corp. (GHIC) to accelerate the development and commercialization of medical technologies and products needed to respond to or prevent future pandemics and other public health emergencies.
Venture capitalists in China are adopting different models to quickly create value from biopharma companies and are able to exit much faster than their U.S counterparts, new data suggest.
Venture capitalists in China are adopting different models to quickly create value from biopharma companies and are able to exit much faster than their U.S counterparts, new data suggest.
Versant Ventures has closed three new funds with an aggregate raise of $950 million to allocate to the next wave of innovative startups across North America and Europe. The money is new, but everything else is more or less unchanged. “It’s the same strategy, same team, same geography, same operational model,” Versant chairman and managing director Brad Bolzon told BioWorld.
The number of venture capital financings completed in March, as well as the total amount they raised for the biopharma industry, are more than any other month in the past 21 years. With 92 rounds worth $6.2 billion, the volume is 35% higher than the September 2020 record of 68, and the total funds are 66% more than the $3.8 billion raised in the next top month of June 2020.
While historical data suggest venture capital rounds will eventually dip below the peak years, biopharma financings completed in recent months indicate the dollars are continuing to climb in 2021. A maturing industry, the high potential of cell and gene therapy products, the advancing technologies of artificial intelligence and machine learning, as well as an eager financial community, are all responsible for the ever-increasing availability of private money.
While historical data suggest venture capital rounds will eventually dip below the peak years, biopharma financings completed in recent months indicate the dollars are continuing to climb in 2021.
The medical device incubator Coridea LLC and the health care investment firm Deerfield Management Co. LP are joining forces to accelerate the formation of med-tech companies on the East Coast.
DUBLIN – Sofinnova Partners closed out its crossover fund at €445 million (US$535 million), a total, it said, that makes it Europe’s largest crossover investor in biotech. It’s almost three years since Paris-based Sofinnova Partners completed an initial close at €275 million. “We didn’t set a bar – we thought between €250 million and €400 million would be great,” Antoine Papiernik, chairman and managing partner at Sofinnova, told BioWorld.
During a panel discussion at Biocom California's Global Life Sciences Partnering Conference, business development executives at various pharmaceutical companies advised biotech companies on everything from funding to manufacturing to deal structure.
